Feature | May 21, 2014

Renal Denervation May Reduce Hypertension in Patients With Renal Artery Stents

Journal of Endovascular Therapy Hypertension Renal Denervation Therapy

May 21, 2014 — Patients with hypertension after renal artery stenting who do not respond to drug treatment may have another option. Renal sympathetic denervation can help lower blood pressure by desensitizing nerve endings in the vascular wall. However, recent studies of this treatment concept have excluded patients with stented renal arteries.

The Journal of Endovascular Therapy presents a proof-of-concept study of 10 patients with renal artery stents who were treated with radiofrequency renal denervation. The study examined office blood pressure and ambulatory blood pressure measurements, medication, and renal assessment at baseline and at three, six and 12 months following the procedure.

In this procedure, a catheter is inserted into the arteries leading to the kidney, and radiofrequency energy is dispensed to a segment of the artery, keeping a safe distance of 5 mm from the stented segments. Once the nerve endings are desensitized, the renal sympathetic activity is reduced and decreased blood pressure can result.

Current international guidelines, however, exclude patients with an artery stent because of concern that application of radiofrequency through a metallic stent might induce restenosis or occlusion. Alternate technologies for producing denervation, such as ultrasound, brachytherapy, and local drug delivery, are also under clinical investigation.

In this study, a successful response to treatment was considered a reduction of at least 10 mm Hg in office blood pressure as well as renal artery patency. Nine of the 10 patients met this goal. The patients showed sustained decreased readings in office blood pressure from baseline to three, six and 12 months. Initial readings averaging about 190/84 mm Hg declined to 158/76 mm Hg after 12 months. No renal artery restenosis or aneurysm had occurred at one year.

While this article makes a case for the expansion of renal denervation studies to include patients with stents, an accompanying commentary points to other trials of this procedure that have not met with the same success. This issue of the journal also includes a case study outlining complications. Also noted are the recently released six-month results of the SYMPLICITY HTN-3 trial comparing renal denervation against a sham procedure. The results show no significant differences between the two approaches. The commentary urges a case-by-case consideration for renal denervation while further research is conducted.

Full text of the article, “Renal Denervation for Hypertension Refractory to Renal Artery Stenting” and commentary article, Journal of Endovascular Therapy, Vol. 21, No. 2, 2014, are now available.

For more information: www.jevtonline.org, www.isesonline.org

Related Content

News | Hypertension| August 27, 2015
August 27, 2015 — Analysis of blood samples from more than 5,000 people suggests that a more sensitive version of a b
ASE, echocardiography, hypertension, document, EACVI, JASE, Thomas H. Marwick
Feature | Cardiovascular Ultrasound| July 07, 2015
A new document from the American Society of Echocardiography (ASE) provides detailed guidance for clinicians on how to...
blood pressure, LDL, medication therapy, coronary plaque, SCAI
News | May 14, 2015
Combining statins for low-density lipoprotein (LDL) and calcium channel antagonists for blood pressure reduces harmful...
Medtronic, SYMPLICITY AF, PVI, renal denervation, Arctic Front, Spyral, G3
Feature | May 05, 2015
Medtronic plc announced the start of a clinical study to determine whether paroxysmal and persistent atrial...
Vessix Renal Denervation System, REDUCE-HTN: REINFORCE, high blood pressure

Vessix System image courtesy of Boston Scientific Corp.

News | May 04, 2015
Boston Scientific Corp. is taking a new approach to evaluate the performance of the Vessix Renal Denervation System,...
News | April 09, 2015
A study including more than 20,000 adults in China found combined use of the hypertension medication enalapril and...
Feature | April 01, 2015
Medtronic plc announced the initiation of the SPYRAL HTN Global Clinical Trial Program, a phased clinical program...
Renal denervation, hypertension, Peregrine System

Image courtesy of Ablative Solutions

News | February 12, 2015
Ablative Solutions Inc. announced the addition of Michael Weber, M.D., FACP, FACC, FAHA, to its Scientific Advisory...
blood pressure, systolic, hypertension, younger adults, cardiovascular, risk
News | February 10, 2015
Younger adults with elevated systolic blood pressure have a higher risk for cardiovascular disease and coronary heart...
Technology | February 05, 2015
Ostar Healthcare Technology announced the North American launch of their Cellular P201 telehealth blood pressure...
Overlay Init